title: Neovascular glaucoma treatment with extraction of anterior chamber fibrovascular tissue.
abstract: The use of antibody to vascular endothelial growth factor to treat neovascular glaucoma yields good anatomic results in most cases. However, this type of glaucoma can cause angle closure with decompensation of intraocular pressure secondary to fibrovascular tissue contraction in the anterior chamber. Our surgical technique treats the cause by removing the anterior chamber fibrous complex after administration of antibody to vascular endothelial growth factor, thus restoring the chamber angle.
authors.affiliation: Department of Vitreoretinal Surgery, Barraquer Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Jeroni
authors.initials: J
authors.lastname: Nadal
authors.forename: Elisa
authors.initials: E
authors.lastname: Carreras
authors.forename: Bachar
authors.initials: B
authors.lastname: Kudsieh
authors.forename: Maribel
authors.initials: M
authors.lastname: Canut
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000867:Anterior Chamber / Q000187:drug effects / Q000601:surgery*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D005355:Fibrosis / Q000601:surgery; D015355:Glaucoma, Neovascular / Q000601:surgery*; D006068:Gonioscopy; D006801:Humans; D007429:Intraocular Pressure; D007498:Iris / Q000473:pathology; D013508:Ophthalmologic Surgical Procedures; D041623:Tomography, Optical Coherence; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D055675:Viscosupplements / Q000008:administration & dosage; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D055675:Viscosupplements; D000068258:Bevacizumab